Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Increased risk of ovarian cancer witnessed in women taking hormone therapy

Compared with women who have never taken hormone therapy, those who currently take it or who have taken it in the past are at increased risk of ovarian cancer, regardless of the duration of use, the formulation, estrogen dose, regimen or route of administration, according to a study in the July 15 issue of JAMA.

1 Sep 2009

Telephone counseling and referral service launched for ovarian cancer affected women

Women with ovarian cancer can now find immediate assistance to better cope with their diagnosis by calling 877-OV-HOPE-1 (877-684-6731), a new, free telephone counseling and referral service launched today by a unique partnership: L'Oreal Paris and its charitable partner, the Ovarian Cancer Research Fund (OCRF), and CancerCare, a national non-profit which provides free counseling and education services to individuals and families affected by cancer.

1 Sep 2009

COCA to conduct meeting on ovarian cancer awareness

The Colorado Ovarian Cancer Alliance (COCA) “March on the Capitol,” on Friday, Sept. 4, noon, features speakers Lt. Gov. Barbara O’Brien, Congresswoman Diana DeGette and Dr. Daniel Donato, gynecological oncologist, Rocky Mountain Cancer Centers.

1 Sep 2009

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the August edition of Biotechnology Focus, Canada's oldest and most successful magazine serving the Canadian life science industry.

31 Aug 2009

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. An initial study in patients conducted jointly by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital has found that the treatment has no unwanted side-effects.

31 Aug 2009

$11.5 million grant to Mayo Clinic Cancer Center to translate research into treatments for women with ovarian cancer

Investigators at the Mayo Clinic Cancer Center have received a five-year, $11.5 million grant to translate research into treatments for women with ovarian cancer.

28 Aug 2009

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

27 Aug 2009

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.

26 Aug 2009

More than half of women with ovarian cancer face delay in diagnosis

Many women with ovarian cancer can go undiagnosed for months because their symptoms are not always being investigated promptly, warn researchers at the University of Bristol in a study published on bmj.com today.

26 Aug 2009

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Tikcro Technologies Ltd. (OTC BB: TIKRF) today reported results for the second quarter and six months ended June 30, 2009.

26 Aug 2009

Orphan drug status granted to BioCancell's BC-819 drug

Tikcro Technologies today announced that the United States (“US”) Department of Health and Human Services ("HHS") has granted orphan drug status to BioCancell's BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer.

24 Aug 2009

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein-a cancer vaccine-that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

21 Aug 2009

U.S. District Court rules against Lilly regarding Gemzar patent

Eli Lilly and Company today announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment.

17 Aug 2009

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

The first batch of NY-ESO-1 recombinant protein produced in a facility supported entirely by non-profit entities has successfully cleared regulatory review and has entered clinical testing. The clinical trials are part of the Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd. (LICR).

13 Aug 2009

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

Holography helps tackle ovarian cancer

Two University of Arizona researchers have formed a research team to design, build and evaluate two versions of an ovarian cancer medical imaging and screening instrument that will use holographic components in a new type of optical microscope.

11 Aug 2009

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease.

11 Aug 2009

Estrogen-dependent switch tempers killing activity of immune cells

The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. The key player in this process is a cytotoxic T cell molecule which has been known for a long time and which scientists have named EBAG9.

10 Aug 2009

Many women at high risk for breast or ovarian cancer choose surgery as a precautionary measure

Many women at high risk for breast or ovarian cancer are choosing to undergo surgery as a precautionary measure to decrease their cancer risk, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

6 Aug 2009

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Increased risk of ovarian cancer witnessed in women taking hormone therapy

Telephone counseling and referral service launched for ovarian cancer affected women

COCA to conduct meeting on ovarian cancer awareness

MabCure featured in the August edition of Biotechnology Focus magazine

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

$11.5 million grant to Mayo Clinic Cancer Center to translate research into treatments for women with ovarian cancer

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

More than half of women with ovarian cancer face delay in diagnosis

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Orphan drug status granted to BioCancell's BC-819 drug

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

U.S. District Court rules against Lilly regarding Gemzar patent

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Holography helps tackle ovarian cancer

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

Estrogen-dependent switch tempers killing activity of immune cells

Many women at high risk for breast or ovarian cancer choose surgery as a precautionary measure

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in